Pear Therapeutics has raised an undisclosed amount of money in a round led by 5AM Ventures, whose Founding Managing Partner Andrew J. Schwab joined the company’s Board of Directors.

Pear makes prescription pharmaceutical-software combination products called eFormulations, which enhance the efficacy of pharmaceutical preparations. The new funds will help the company build a portfolio of eFormulations; the company is initially focused on disorders of the brain, many of which impose large societal costs and yet still have limited treatment options.

“From mobile applications, to virtual reality simulations, to predictive analytics, our technology directly boosts medication efficacy in incredibly significant ways, well beyond enhanced compliance,” said Corey McCann, Pear Therapeutics’ President and CEO. “Our team has pulled together the pieces required to deliver these products to patients.”

Pear Therapeutics has offices in Boston and San Francisco; its patented approach provides better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payors.